When President Trump announced the broad strokes of his drug price reform initiative, some of these measures seemed on target to benefit the biosimilars industry. However long awaited, makers of originator biologics seemed not to be worried about its implications. The President may not be able to effect much change, without causing unintended adverse consequences. … Continue reading How Will Biosimilars Be Affected by Trump’s Drug Price Reform Measures?
Tag: President Trump
How Trump’s Tariffs May Hit Drug Pricing
When President Trump decided to implement tariffs on the imports of Chinese products, he wasn’t talking only about steel and textiles. According to the association representing the generic drug industry, the active ingredients of many pharmaceuticals—including biologics and biosimilars—could also be affected. Physicians and patients are largely unaware of where their medications are actually manufactured. … Continue reading How Trump’s Tariffs May Hit Drug Pricing